Format

Send to

Choose Destination
See comment in PubMed Commons below
Int Urol Nephrol. 2001;33(3):407-12.

Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.

Author information

  • 1Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. Jpool@bcm.tmc.edu

Abstract

Alpha1-adrenoceptor antagonists have been shown to provide effective relief from symptoms of benign prostatic hyperplasia (BPH) with attendant improvements in quality of life. Although the alpha1A-adrenoceptor subtype predominates over other subtypes of alpha1 adrenoceptors in the prostate gland, there is no evidence that a subselective alpha-adrenoceptor antagonist provides a clinical advantage over a selective alpha1-adrenoceptor antagonist in the treatment of patients with BPH. The pharmacokinetic profiles of alpha1A-adrenoceptor antagonists and their documented penetration of the blood-brain barrier (CNS adverse effects) preclude a clinical benefit of subselective alpha-adrenoceptor blockers over selective alpha1 blockers.

PMID:
12230262
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk